Scholarlink

<p>Gastric and gastroesophageal junction adenocarcinoma (GC/GEJC) poses a substantial clinical burden in China. This updated guideline introduces a refined human epidermal growth factor receptor 2 (HER2) classification system (high, intermediate, low, absent) to redefine patient stratification for targeted therapy. It integrates cutting-edge evidence on standardized detection—including immunohistochemistry, in situ hybridization, and liquid biopsy—to overcome spatial–temporal heterogeneity. Recent progress in the use of HER2-targeted agents, including monoclonal antibodies, antibody–drug conjugates, tyrosine kinase inhibitors, and bispecific antibodies, is systematically reviewed and presented to inform evidence-based clinical practice. These updates aim to optimize personalized HER2-targeted therapy and improve outcomes in GC/GEJC patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Chinese guidelines for HER2-targeted therapy in gastric and gastroesophageal junction adenocarcinoma (2025 Edition)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月8日

查看全文
  • Xiaotian Zhang,
  • Yakun Wang,
  • Muyan Cai,
  • Fenghua Wang,
  • Tong Xie,
  • Jianming Ying,
  • Weiqi Sheng,
  • Xiangshan Fan,
  • Xiujuan Qu,
  • Chang Wang,
  • Zhi Peng,
  • Jie’er Ying,
  • Miaozhen Qiu,
  • Tianshu Liu,
  • Yueping Liu,
  • Dongmei Lin,
  • Xiaohong Yao,
  • Ziyu Li,
  • Wenlong Guan,
  • Ruihua Xu,
  • Jin Li,
  • Hong Bu,
  • Lin Shen

摘要

Gastric and gastroesophageal junction adenocarcinoma (GC/GEJC) poses a substantial clinical burden in China. This updated guideline introduces a refined human epidermal growth factor receptor 2 (HER2) classification system (high, intermediate, low, absent) to redefine patient stratification for targeted therapy. It integrates cutting-edge evidence on standardized detection—including immunohistochemistry, in situ hybridization, and liquid biopsy—to overcome spatial–temporal heterogeneity. Recent progress in the use of HER2-targeted agents, including monoclonal antibodies, antibody–drug conjugates, tyrosine kinase inhibitors, and bispecific antibodies, is systematically reviewed and presented to inform evidence-based clinical practice. These updates aim to optimize personalized HER2-targeted therapy and improve outcomes in GC/GEJC patients.